KR20050107611A - 구아니딘 유도체 및 신경펩티드 ff 수용체 길항제로서이들의 용도 - Google Patents

구아니딘 유도체 및 신경펩티드 ff 수용체 길항제로서이들의 용도 Download PDF

Info

Publication number
KR20050107611A
KR20050107611A KR1020057016769A KR20057016769A KR20050107611A KR 20050107611 A KR20050107611 A KR 20050107611A KR 1020057016769 A KR1020057016769 A KR 1020057016769A KR 20057016769 A KR20057016769 A KR 20057016769A KR 20050107611 A KR20050107611 A KR 20050107611A
Authority
KR
South Korea
Prior art keywords
tetrahydro
guanidine
benzothiazol
formate
thiazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057016769A
Other languages
English (en)
Korean (ko)
Inventor
에바 카로프
마티아스 스테게르
올리버 발데네이레
안자 프레처
볼케르 부레우
쿠르트 힐페르트
헤인즈 프레츠
토마스 길레르
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20050107611A publication Critical patent/KR20050107611A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057016769A 2003-03-20 2004-03-22 구아니딘 유도체 및 신경펩티드 ff 수용체 길항제로서이들의 용도 Withdrawn KR20050107611A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4662003 2003-03-20
CH466/03 2003-03-20

Publications (1)

Publication Number Publication Date
KR20050107611A true KR20050107611A (ko) 2005-11-14

Family

ID=32996985

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016769A Withdrawn KR20050107611A (ko) 2003-03-20 2004-03-22 구아니딘 유도체 및 신경펩티드 ff 수용체 길항제로서이들의 용도

Country Status (15)

Country Link
US (1) US7727979B2 (https=)
EP (1) EP1608662A1 (https=)
JP (1) JP2006520330A (https=)
KR (1) KR20050107611A (https=)
CN (1) CN100355758C (https=)
AR (1) AR043662A1 (https=)
AU (1) AU2004222224A1 (https=)
BR (1) BRPI0408357A (https=)
CA (1) CA2518679A1 (https=)
CL (1) CL2004000553A1 (https=)
MX (1) MXPA05009855A (https=)
NO (1) NO20054743L (https=)
RU (1) RU2337911C2 (https=)
TW (1) TW200510434A (https=)
WO (1) WO2004083218A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
ATE496036T1 (de) * 2004-03-19 2011-02-15 Dipharma Francis Srl Zwischenprodukte für die herstellung von pramipexol
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
AU2008260647A1 (en) 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
US11491136B2 (en) 2017-02-14 2022-11-08 Research Triangle Institute Proline-based neuropeptide FF receptor modulators
EP3762008A1 (en) * 2018-03-09 2021-01-13 Centre National de la Recherche Scientifique Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment
CN110093348B (zh) * 2018-12-05 2022-11-29 西北工业大学 增强小鼠NPFFR2基因表达的shRNA
KR20220044721A (ko) 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물
CN112341404B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 噻唑类衍生物或盐、异构体、其制备方法及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
SU664965A1 (ru) * 1977-02-01 1979-05-30 Уральский ордена Трудового Красного Знамени политехнический институт им.С.М.Кирова 3-Замещенные пиридо /2,3-е/-1,2,4тиадиазин-1,1-диоксиды,обладающие анальгетическим действием
GB8333514D0 (en) * 1983-12-16 1984-01-25 Erba Farmitalia Tetrahydrothiazolo(5 4-c)pyridine derivatives
JPS60226810A (ja) 1984-04-25 1985-11-12 Ikeda Mohandou:Kk 抗潰瘍剤
GB2173187B (en) * 1985-03-23 1988-05-18 Erba Farmitalia Condensed 2-substituted thiazole derivatives
JPS6233158A (ja) 1985-08-02 1987-02-13 Shionogi & Co Ltd ベンズイミダゾ−ル誘導体および抗潰瘍剤
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
FR2814367B1 (fr) * 2000-09-25 2008-12-26 Inst Nat Sante Rech Med Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.

Also Published As

Publication number Publication date
BRPI0408357A (pt) 2006-03-21
JP2006520330A (ja) 2006-09-07
AU2004222224A1 (en) 2004-09-30
US20060194788A1 (en) 2006-08-31
CA2518679A1 (en) 2004-09-30
NO20054743L (no) 2005-10-14
RU2337911C2 (ru) 2008-11-10
WO2004083218A1 (de) 2004-09-30
EP1608662A1 (de) 2005-12-28
US7727979B2 (en) 2010-06-01
CL2004000553A1 (es) 2005-02-04
AR043662A1 (es) 2005-08-03
TW200510434A (en) 2005-03-16
CN1761673A (zh) 2006-04-19
CN100355758C (zh) 2007-12-19
MXPA05009855A (es) 2005-12-06
RU2005132308A (ru) 2006-03-20

Similar Documents

Publication Publication Date Title
KR20050107611A (ko) 구아니딘 유도체 및 신경펩티드 ff 수용체 길항제로서이들의 용도
JP6604664B2 (ja) 核内受容体に対して活性な化合物
KR101724161B1 (ko) 세포내 칼슘을 조절하는 화합물
JP6626454B2 (ja) Trpa1モジュレーター
JP2012532107A (ja) スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用
JP6417324B2 (ja) τリン酸化を阻害する方法
JP2003516390A (ja) ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
JP2010522690A (ja) 三環式スピロオキシインドール誘導体および治療薬としてのその使用
CN119118926A (zh) Kv7通道激活剂组合物和使用方法
JP7300552B2 (ja) 縮合環ピリミジンアミノ化合物、その調製方法、医薬組成物及び使用
WO2008046065A1 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
JP4262092B2 (ja) LH作動活性とFSH作動活性を合わせ持つチエノ[2,3−d]ピリミジン誘導体
US7087756B2 (en) Isoxazolopyridinones
JP2001522839A (ja) 新規レセプター及び当該レセプターに結合する化合物
JP2002529458A (ja) PPAR−γリガンド
US10947251B2 (en) Therapeutic compounds and methods of use thereof
CN103827100B (zh) 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物
ZA200508486B (en) Guanidine derivatives and use thereof as neuropeptide FF receptor antagonists
RU2815636C1 (ru) Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid